Selpercatinib for Non-Small Cell Lung Cancer
Study Summary
This trial is testing a new drug to see if it can prevent cancer from returning in people who have had surgery or radiation for early-stage lung cancer. It will last up to three years, and people whose cancer comes back while taking the placebo will be able to switch to the new drug.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
Are there any other treatments that have been studied alongside Selpercatinib?
"Selpercatinib was first trialed in 2017 at the Severance Hospital. Since then, 18301 have completed clinical trials across the globe. There are 11 active trials as of now, with a significant portion taking place in Toronto, Canada."
What are the precedents for this research?
"Selpercatinib has been under investigation since 2017 by Eli Lilly and Company. The first study, involving 875 participants, occurred in that year. Selpercatinib received Phase 1 & 2 approval after the successful trial. There are currently 11 active studies for Selpercatinib taking place in 584 cities across 34 countries."
Are we able to sign new participants up for this experiment?
"Yes, according to the latest information on clinicaltrials.gov, this trial is looking for 170 patients at 22 different sites. The posting date was December 20th, 2021 and the most recent update was November 10th, 2022."
Has the U.S. Food and Drug Administration okayed Selpercatinib?
"Selpercatinib's safety was given a score of 3 by our analysts. This is due to the fact that Selpercatinib has reached Phase 3 in clinical trials, so there is both efficacy and safety data available."
How many different medical clinics are running this trial today?
"22 hospitals and medical research institutes are currently taking part in this study. These include locations in Toronto, Clifton Park, Boston as well as other cities. If you enroll, try to select the site that is closest to your residence to reduce travel time and expenses."
How many people are currently enrolled in this clinical trial?
"One hundred and seventy patients that meet the necessary requirements are required for this clinical trial. The sponsor, Eli Lilly and Company, will be managing the study from multiple locations including Princess Margaret Hospital in Toronto, Ontario and New York Oncology Hematology, P.C in Clifton Park, Massachusetts."